{"id":48647,"date":"2022-09-21T14:02:05","date_gmt":"2022-09-21T12:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/"},"modified":"2022-09-21T14:02:05","modified_gmt":"2022-09-21T12:02:05","slug":"nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/","title":{"rendered":"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel"},"content":{"rendered":"
\n

\nCombining the power of spatial biology and AI, Propath and Nucleai push the boundaries of pathology tissue analytics to develop a novel, high multiplexed immunofluorescence (IF) panel and associated AI-powered algorithm for biomarker discovery and development <\/b>\n<\/p>\n

<\/a>
<\/a><\/p>\n

HEREFORD, United Kingdom & TEL AVIV, Israel–(BUSINESS WIRE)–#aipowered<\/a>—Propath UK<\/a>, Europe\u2019s leading CRO for spatial biology, and Nucleai<\/a>, a leader in AI-powered spatial biology transforming precision medicine by unlocking spatial biology insights from pathology data, announce their collaboration to develop and validate a 30-plex immunofluorescence (IF) panel focused on protein targets relevant to immuno-oncology. For our pharmaceutical and biotechnology partners, this groundbreaking panel, in conjunction with Nucleai’s validated AI assay, can be used to unlock insights from immunotherapy trials and inform the development of novel biomarkers and companion diagnostics (CDx).\n<\/p>\n

\n\u201cOur strategic partnership with Propath has far-reaching implications in biomarker discovery,\u201d said Avi Viedman, CEO of Nucleai. \u201cThe collaboration allows us to develop and deploy AI-based multi-modal models to identify unique sets of previously unavailable biomarkers and drug targets. Together, we are pushing the boundaries of pathology tissue analytics.\u201d\n<\/p>\n

\nApplying its expertise in multiomic spatial biology and high-plex immunofluorescence, Propath will develop a novel protocol using the innovative Lunaphore COMET<\/a>\u2122 platform for analysis of 30 high-value protein targets from a single tissue section. The COMET\u2122 enables rapid development of highly multiplexed panels, with robust and reproducible staining. Propath UK will use experience gained across a range of spatial proteomic and transcriptomic projects completed on its in-house multiomic platforms.\n<\/p>\n

\n\u201cSpatial biology is transforming biopharma research by enabling deeper analysis of cell phenotypes with full spatial context in the tissue microenvironment,\u201d commented Dr Krish Soni, Chief Executive of Propath UK. \u201cWe are delighted to collaborate with Nucleai on this ambitious project which will empower researchers to unlock the potential of spatial biology, with relevance to programs from discovery through to translational and clinical research.\u201d\n<\/p>\n

\nNucleai\u2019s collaboration with Propath comes on the heels of the recent news announcement that it made with Lunaphore, announcing their partnership to provide AI-powered spatial biology analysis to accelerate drug discovery. This three-way synergy between Propath, Lunaphore and Nucleai brings new capabilities to pharma companies. The partnership utilizes Lunaphore\u2019s flagship COMET\u2122 platform for hyperplex staining and imaging with Nucleai\u2019s cutting-edge AI spatial models to derive new insights from tissue biopsies, including novel drug targets, mechanisms of action, and biomarkers to advance the field of precision medicine. Demonstrating the utility of the technology, Propath provides high-plex tissue analytics using the Lunaphore COMET\u2122 as a fully managed service.\n<\/p>\n

\nNucleai\u2019s proprietary AI-powered, pathology-based biomarker discovery platform combined with Propath\u2019s multiomic spatial biology and high-plex immunofluorescence will accelerate the pharmaceutical industry\u2019s drug development and research programs. A fundamental aspect of precision oncology is predicting drug response for a patient cohort. The combined expertise will allow computational analysis of the tumor microenvironment, feature selections to predict disease prognosis and drug response including cancer sub-type determination, to stratify patients and support early detection and prognosis.\n<\/p>\n

\nAbout Propath UK<\/b>\n<\/p>\n

\nPropath UK is a specialist CRO providing research services in molecular pathology, spatial biology and histopathology for the global biopharmaceutical sector. The company offers a range of technologies for spatial proteomic and transcriptomic tissue analysis, including the NanoString GeoMx and CosMx, the Lunaphore COMET\u2122 and the Akoya PhenoCycler-Fusion\u2122. Propath\u2019s reputation has been gained across 35 years by providing a consistent and responsive service across thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk<\/a>.\n<\/p>\n

\nAbout Nucleai<\/b>\n<\/p>\n

\nNucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking and analyzing the valuable information in the pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making. For more information, please visit www.nucleai.ai<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDave Swatman<\/b>
Commercial Director
\n
Propath UK
\n
Email: daveswatman@propath.co.uk<\/a>\n<\/p>\n

\nMridula Iyer Ph.D<\/b>
VP Strategic Partnerships
\n
Nucleai
\n
Email: mridula.iyer@nucleai.ai<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Combining the power of spatial biology and AI, Propath and Nucleai push the boundaries of pathology tissue analytics to develop a novel, high multiplexed immunofluorescence (IF) panel and associated AI-powered algorithm for biomarker discovery and development HEREFORD, United Kingdom & TEL AVIV, Israel–(BUSINESS WIRE)–#aipowered—Propath UK, Europe\u2019s leading CRO for spatial biology, and Nucleai, a leader … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48647","6":"format-standard","7":"category-industry"},"yoast_head":"\nNucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Combining the power of spatial biology and AI, Propath and Nucleai push the boundaries of pathology tissue analytics to develop a novel, high multiplexed immunofluorescence (IF) panel and associated AI-powered algorithm for biomarker discovery and development HEREFORD, United Kingdom & TEL AVIV, Israel–(BUSINESS WIRE)–#aipowered—Propath UK, Europe\u2019s leading CRO for spatial biology, and Nucleai, a leader ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T12:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220921005207\/en\/1578087\/21\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel\",\"datePublished\":\"2022-09-21T12:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/\"},\"wordCount\":681,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005207\\\/en\\\/1578087\\\/21\\\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/\",\"name\":\"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005207\\\/en\\\/1578087\\\/21\\\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg\",\"datePublished\":\"2022-09-21T12:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005207\\\/en\\\/1578087\\\/21\\\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005207\\\/en\\\/1578087\\\/21\\\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/","og_locale":"en_US","og_type":"article","og_title":"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel - Pharma Trend","og_description":"Combining the power of spatial biology and AI, Propath and Nucleai push the boundaries of pathology tissue analytics to develop a novel, high multiplexed immunofluorescence (IF) panel and associated AI-powered algorithm for biomarker discovery and development HEREFORD, United Kingdom & TEL AVIV, Israel–(BUSINESS WIRE)–#aipowered—Propath UK, Europe\u2019s leading CRO for spatial biology, and Nucleai, a leader ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-21T12:02:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220921005207\/en\/1578087\/21\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel","datePublished":"2022-09-21T12:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/"},"wordCount":681,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220921005207\/en\/1578087\/21\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/","url":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/","name":"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220921005207\/en\/1578087\/21\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg","datePublished":"2022-09-21T12:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220921005207\/en\/1578087\/21\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220921005207\/en\/1578087\/21\/CD4_GREEN%2C_CD8_ORANGE%2C_PD-1_RED%2C_PD-L1_MAGENTA%2C_FOXP3_WHITE%2C_DAPI_BLUE.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nucleai-and-propath-uk-announce-partnership-for-end-to-end-ai-powered-spatial-analysis-of-a-30-plex-immunofluorescence-immuno-oncology-panel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48647"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48647\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}